Bryan, Garnier & Co's News

Ipsen: Cabometyx approved by the FDA two months ahead of schedule

BUY-Top Picks, Fair Value EUR60 (+14%)
News published on
April Tuesday 26, 2016


Ipsen’s recently partnered drug cabozantinib was approved yesterday in the US by the FDA in 2nd line RCC, well ahead of schedule. Top-line OS data are included in the press release (HR=0.66)


For more information, please contact marketing@bryangarnier.com